share_log

Prometheus Biosciences Analyst Ratings

Prometheus Biosciences Analyst Ratings

普罗米修斯生物科学分析师评级
Benzinga Analyst Ratings ·  2023/01/31 09:23
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/31/2023 25.47% Goldman Sachs $117 → $144 Maintains Buy
12/08/2022 23.73% Credit Suisse $59 → $142 Maintains Outperform
12/08/2022 57.71% BTIG $74 → $181 Maintains Buy
12/08/2022 8.91% Oppenheimer $61 → $125 Maintains Outperform
12/08/2022 -3.28% RBC Capital $66 → $111 Maintains Outperform
11/01/2022 -52.08% Stifel $50 → $55 Maintains Buy
10/04/2022 -43.36% Oppenheimer $50 → $65 Maintains Outperform
10/04/2022 -42.49% RBC Capital $61 → $66 Maintains Outperform
10/03/2022 -35.52% BTIG $62 → $74 Maintains Buy
08/29/2022 -41.62% Piper Sandler $53 → $67 Maintains Overweight
08/29/2022 -38.14% Wells Fargo $51 → $71 Maintains Overweight
08/12/2022 -48.59% Credit Suisse $52 → $59 Maintains Outperform
08/12/2022 -47.72% SVB Leerink $55 → $60 Maintains Outperform
07/20/2022 -55.56% Goldman Sachs → $51 Initiates Coverage On → Buy
06/10/2022 -53.82% Piper Sandler → $53 Initiates Coverage On → Overweight
05/13/2022 -60.79% RBC Capital $46 → $45 Maintains Outperform
05/13/2022 -55.56% Wells Fargo $53 → $51 Maintains Overweight
03/10/2022 -54.69% Credit Suisse $50 → $52 Maintains Outperform
03/10/2022 -53.82% Wells Fargo $42 → $53 Maintains Overweight
03/10/2022 -52.08% SVB Leerink $47 → $55 Maintains Outperform
02/11/2022 -45.98% BTIG → $62 Initiates Coverage On → Buy
12/13/2021 -59.92% RBC Capital → $46 Initiates Coverage On → Outperform
12/08/2021 -63.41% Wells Fargo → $42 Initiates Coverage On → Overweight
12/08/2021 -56.43% Oppenheimer $35 → $50 Upgrades Perform → Outperform
12/08/2021 -59.05% SVB Leerink $43 → $47 Maintains Outperform
11/15/2021 — Oppenheimer Downgrades Outperform → Perform
11/15/2021 -62.53% SVB Leerink $34 → $43 Maintains Outperform
10/05/2021 -69.5% Oppenheimer → $35 Initiates Coverage On → Outperform
04/06/2021 -65.15% Guggenheim → $40 Initiates Coverage On → Buy
04/06/2021 -78.22% Stifel → $25 Initiates Coverage On → Buy
04/06/2021 -70.38% SVB Leerink → $34 Initiates Coverage On → Outperform
04/06/2021 -73.86% Credit Suisse → $30 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
01/31/2023 25.47% 高盛 $117 → $144 维护 买
12/08/2022 23.73% 瑞士信贷 $59 → $142 维护 跑赢大盘
12/08/2022 57.71% BTIG $74 → $181 维护 买
12/08/2022 8.91% 奥本海默 $61 → $125 维护 跑赢大盘
12/08/2022 -3.28% 加拿大皇家银行资本 $66 → $111 维护 跑赢大盘
11/01/2022 -52.08% Stifel $50 → $55 维护 买
10/04/2022 -43.36% 奥本海默 $50 → $65 维护 跑赢大盘
10/04/2022 -42.49% 加拿大皇家银行资本 $61 → $66 维护 跑赢大盘
10/03/2022 -35.52% BTIG $62 → $74 维护 买
08/29/2022 -41.62% 派珀·桑德勒 $53 → $67 维护 超重
08/29/2022 -38.14% 富国银行 $51 → $71 维护 超重
08/12/2022 -48.59% 瑞士信贷 $52 → $59 维护 跑赢大盘
08/12/2022 -47.72% SVB Leerink $55 → $60 维护 跑赢大盘
07/20/2022 -55.56% 高盛 → $51 开始承保 →购买
06/10/2022 -53.82% 派珀·桑德勒 → $53 开始承保 →超重
05/13/2022 -60.79% 加拿大皇家银行资本 $46 → $45 维护 跑赢大盘
05/13/2022 -55.56% 富国银行 $53 → $51 维护 超重
03/10/2022 -54.69% 瑞士信贷 $50 → $52 维护 跑赢大盘
03/10/2022 -53.82% 富国银行 $42 → $53 维护 超重
03/10/2022 -52.08% SVB Leerink $47 → $55 维护 跑赢大盘
02/11/2022 -45.98% BTIG → $62 开始承保 →购买
12/13/2021 -59.92% 加拿大皇家银行资本 → $46 开始承保 →跑赢大盘
12/08/2021 -63.41% 富国银行 → $42 开始承保 →超重
12/08/2021 -56.43% 奥本海默 $35 → $50 升级 →表现强于大盘
12/08/2021 -59.05% SVB Leerink $43 → $47 维护 跑赢大盘
11/15/2021 — 奥本海默 评级下调 超越→表现
11/15/2021 -62.53% SVB Leerink $34 → $43 维护 跑赢大盘
10/05/2021 -69.5% 奥本海默 → $35 开始承保 →跑赢大盘
04/06/2021 -65.15% 古根海姆 → $40 开始承保 →购买
04/06/2021 -78.22% Stifel → $25 开始承保 →购买
04/06/2021 -70.38% SVB Leerink → $34 开始承保 →跑赢大盘
04/06/2021 -73.86% 瑞士信贷 → $30 开始承保 →跑赢大盘

What is the target price for Prometheus Biosciences (RXDX)?

普罗米修斯生物科学公司(RXDX)的目标价是多少？

The latest price target for Prometheus Biosciences (NASDAQ: RXDX) was reported by Goldman Sachs on January 31, 2023. The analyst firm set a price target for $144.00 expecting RXDX to rise to within 12 months (a possible 25.47% upside). 21 analyst firms have reported ratings in the last year.

高盛于2023年1月31日报道了普罗米修斯生物科学公司(纳斯达克：RXDX)的最新目标价。这家分析公司将目标价定为144.00美元，预计RXDX将在12个月内上涨至25.47%(可能上涨25.47%)。去年有21家分析公司公布了评级。

What is the most recent analyst rating for Prometheus Biosciences (RXDX)?

普罗米修斯生物科学公司(RXDX)的最新分析师评级是多少？

The latest analyst rating for Prometheus Biosciences (NASDAQ: RXDX) was provided by Goldman Sachs, and Prometheus Biosciences maintained their buy rating.

普罗米修斯生物科学公司(纳斯达克代码：RXDX)的最新分析师评级由高盛提供，普罗米修斯生物科学公司维持其买入评级。

When is the next analyst rating going to be posted or updated for Prometheus Biosciences (RXDX)?

普罗米修斯生物科学公司(RXDX)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prometheus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prometheus Biosciences was filed on January 31, 2023 so you should expect the next rating to be made available sometime around January 31, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公开财务报表，与普罗米修斯生物科学公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。普罗米修斯生物科学公司的上一次评级是在2023年1月31日提交的，所以你应该预计下一次评级将在2024年1月31日左右的某个时候公布。

Is the Analyst Rating Prometheus Biosciences (RXDX) correct?

分析师对普罗米修斯生物科学公司(RXDX)的评级正确吗？

While ratings are subjective and will change, the latest Prometheus Biosciences (RXDX) rating was a maintained with a price target of $117.00 to $144.00. The current price Prometheus Biosciences (RXDX) is trading at is $114.77, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的普罗米修斯生物科学公司(Prometheus Biosciences)的评级保持不变，目标价在117.00美元至144.00美元之间。普罗米修斯生物科学公司目前的交易价格为114.77美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发